Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CV Sciences (CVSI) EBITDA Margin (2016 - 2025)

CV Sciences (CVSI) has disclosed EBITDA Margin for 13 consecutive years, with 2.27% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 1436.0% to 2.27% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3.41% through Dec 2025, up 1054.0% year-over-year, with the annual reading at 3.41% for FY2025, 1054.0% up from the prior year.
  • EBITDA Margin hit 2.27% in Q4 2025 for CV Sciences, up from 8.45% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 138.91% in Q1 2023 to a low of 177.96% in Q4 2021.
  • Historically, EBITDA Margin has averaged 23.45% across 5 years, with a median of 16.06% in 2024.
  • Biggest five-year swings in EBITDA Margin: surged 25517bps in 2022 and later crashed -17186bps in 2023.
  • Year by year, EBITDA Margin stood at 177.96% in 2021, then surged by 143bps to 77.2% in 2022, then crashed by -223bps to 94.66% in 2023, then skyrocketed by 82bps to 16.63% in 2024, then skyrocketed by 86bps to 2.27% in 2025.
  • Business Quant data shows EBITDA Margin for CVSI at 2.27% in Q4 2025, 8.45% in Q3 2025, and 3.62% in Q2 2025.